Surgery
Volume 131, Issue 6 , Pages 595-600 , June 2002

Ubiquitin proteasome inhibition and cancer therapy

,Accepted 18 November 2001.

References 

  1. Lee DH, Goldberg AL. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 1998;8:397–403
  2. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell. 1994;79:13–21
  3. Rock K, Gramm C, Rothstein L, Clark K, Stein R, Dick L, et al.  Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. 1994;78:761–777
  4. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science. 1995;268:726–731
  5. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res. 1999;5:2638–2645
  6. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, et al.  Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett. 1998;8:333–338
  7. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al.  Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59:2615–2622
  8. Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliot P, et al.  26S proteasome inhibition induces apoptosis and limits growth in human pancreatic cancer. J Cell Biochem. 2001;82:110–122
  9. Pagano M, Tam SW, Theodoras AM, Beer-Romano P, Del Sal G, Chau V, et al.  Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 1995;267:1022–1024
  10. Maki CG, Huibregtse JM, Howley PM. In vivo ubiquination and proteasome-mediated degradation of p53. Cancer Res. 1996;56:2649–2654
  11. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, et al.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997;3:231–234
  12. Ahrendt SA, Brown HM, Komorowski RA, Zhu Y, Wilson SD, Erickson BA, et al.  p21WAF1 expression is associated with improved survival after adjuvant chemoradiation for pancreatic cancer. Surgery. 2000;128:120–130
  13. Palombella VJ, Rando OK, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 1994;78:773–785
  14. Wang CY, Mayo MW, Baldwin AS. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappa B. Science. 1996;274:784–787
  15. Wang CY, Cusack JC, Liu R, Baldwin AS. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappa B. Nat Med. 1999;5:412–417
  16. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS. NF-(B antiapoptosis: induction of TRAF1, TRAF2, c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998;281:1680–1683
  17. Huang TT, Wuerzberger-Davis SM, Seufzer BJ, Shumway SD, Kurama T, Boothman DA, et al.  NF-kappa B activation by campothecin. J Biol Chem. 2000;275:9509
  18. Stinchcombe TE, Mitchell BS, Depcik-Smith N, Adams J, Elliott P, Shea TC, et al.  PS-341 is active in multiple myeloma: preliminary report of a phase I trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies. Blood. 2000;96:516a
  19. Aghajanian C, Elliott P, Adams J, Soignet S, Spriggs DR. Phase I trial of the proteasome inhibitor PS-341 in advanced malignancy. ASCO Proceedings. 2000;19:189a

☆ Reprint requests: Mark P. Callery, MD, FACS, Division of General Surgery, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215.

PII: S0039-6060(02)00002-8

doi: 10.1067/msy.2002.121890

Surgery
Volume 131, Issue 6 , Pages 595-600 , June 2002

Article Tools

* Image Usage & Resolution